Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).

Autor:	Borges Mde F; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Franciscon Pde M; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Cambraia TC; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Oliveira DM; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Ferreira BP; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Resende EA; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil., Palhares HM; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
Jazyk:	angličtina
Zdroj:	Archives of endocrinology and metabolism [Arch Endocrinol Metab] 2015 Dec; Vol. 59 (6), pp. 515-22. Date of Electronic Publication: 2015 Sep 25.
DOI:	10.1590/2359-3997000000101
Abstrakt:	Objective: To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment. Subjects and Methods: Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/monthly, were selected, and divided into 4 groups: group 1 (G1), 25 girls who attained FH; group 2 (G2), 18 girls who completed treatment but did not reach FH; group 3 (G3), 11 girls still under treatment; and group 4 (G4), 8 boys, 5 of which attained FH. Treatment was concluded at a bone age of 12 years, and follow-up continued until FH was achieved. Results: In both G1 and G2 groups, height standard deviation score (SDS), weight-SDS and percentile of body mass index (PBMI) did not show intra/intergroup differences at the beginning and at interruption of treatment, but when added, G1+G2, height-SDS and weight-SDS differed significantly (p = 0.002 and 0.0001, respectively). In G1, 19 of 25 cases attained TH, and average height gain was 16.7 cm (7.7- 27.1); there was significant difference between FH and prediction of FH at the start (PFH at start) (p = 0.0001), as well as between PFH at interruption vs TH and vs FH (p = 0.007) with FH higher than TH (p = 0.004). Significant correlation was identified between FH and height gain after treatment. Conclusion: As shown by some studies, GnRH analogue treatment was effective in children with CPP reaching FH near the genetic target.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu